A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae254 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Anne-Marie Chaftari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control and Employee Health, Unit 1460, The University of Texas MD Anderson Cancer Center, 1515 Holcombe…. Hauptthemen laut MEDLINE: Febrile Neutropenia, Anti-Bacterial Agents, Neoplasms, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, The University of Texas MD Anderson Cancer Center Support, Grant.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Antibiotic overuse leads to the emergence of antibiotic resistance that threatens immunocompromised cancer patients. Infections caused by MDR Gram-negative pathogens are difficult to treat and associated with high mortality. Hence, empirical therapy with standard-of-care (SOC) antibiotics could be suboptimal in these vulnerable patients. New antibiotics covering potential resistant pathogens may be considered.
Methods
We conducted a randomized non-inferiority study comparing safety and efficacy of imipenem/cilastatin/relebactam (IPM/REL), a β-lactam/β-lactamase inhibitor combination, with SOC antibiotics (cefepime, piperacillin/tazobactam or meropenem) in cancer patients with febrile neutropenia. Patients received at least 48 h of IV antibiotics and were assessed at end-of-IV (EOIV) therapy, test of cure (TOC; Days 21–28), and late follow-up (LFU; Days 35–42).
Results
A total of 100 patients were enrolled (49 IPM/REL and 50 SOC). Demographics and rates of documented microbiological infections were similar in both groups. In the SOC arm, 86% of antibiotics consisted of cefepime. Patients on IPM/REL had a higher favourable clinical response at EOIV than those on SOC (90% versus 74%; P = 0.042); however, responses were similar at TOC and LFU. Microbiological eradication was comparable at all three timepoints. Study drug-related adverse events and adverse events leading to drug discontinuation were similar in both groups, with no study drug-related mortality.
Conclusions
Our results suggest that compared with SOC antibiotics, predominantly cefepime, IPM/REL for empirical coverage of febrile neutropenia in cancer patients is generally safe and could be associated with a better clinical outcome at EOIV. The current SOC consisting mainly of agents that do not cover for ESBL-producing and carbapenem-resistant Enterobacterales bacteria should be reconsidered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Infection Control and Employee Health, Unit 1460, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
- Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Teny John, Ying Yuan, Issam Raad
Förderung
- NCI NIH HHS
- The University of Texas MD Anderson Cancer Center Support
- Grant
- Merck & Co
- National Institutes of Health/National Cancer Institute
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Chaftari, A. M., Dagher, H., Hachem, R., Jiang, Y., Lamie, P., Wilson Dib, R., John, T., Haddad, A., Philip, A., Alii, S., Mulanovich, P., Yuan, Y., Chaftari, P., & Raad, I. (2024). A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae254
Vancouver
Chaftari AM, Dagher H, Hachem R, Jiang Y, Lamie P, Wilson Dib R, et al. A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae254
BibTeX
@article{Chaftari2024,
author = {Chaftari, Anne-Marie and Dagher, Hiba and Hachem, Ray and Jiang, Ying and Lamie, Peter and Wilson Dib, Rita and John, Teny and Haddad, Andrea and Philip, Ann and Alii, Shahnoor and Mulanovich, Patricia and Yuan, Ying and Chaftari, Patrick and Raad, Issam},
title = {A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae254}
}
EUVIMED